Q3 EPS Forecast for Monte Rosa Therapeutics Cut by Analyst

Key Points

• Wedbush has downgraded Monte Rosa Therapeutics' Q3 2025 earnings per share estimate from ($0.25) to ($0.50), with the full-year earnings estimate now at ($1.49) per share.
• Wall Street Zen has changed Monte Rosa's rating from "buy" to "hold," while the stock still maintains a consensus rating of "Moderate Buy" with a target price of $15.33.
• Monte Rosa Therapeutics' stock opened at $6.47 and has been down 6.6%, with a market cap of approximately $399.59 million.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Research analysts at Wedbush reduced their Q3 2025 earnings per share estimates for shares of Monte Rosa Therapeutics in a report released on Monday, September 15th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.50) for the quarter, down from their prior forecast of ($0.25). The consensus estimate for Monte Rosa Therapeutics' current full-year earnings is ($1.49) per share. Wedbush also issued estimates for Monte Rosa Therapeutics' Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.26) EPS.

Monte Rosa Therapeutics Price Performance

Shares of GLUE stock traded down $0.60 during trading hours on Wednesday, hitting $6.33. The stock had a trading volume of 1,364,596 shares, compared to its average volume of 2,196,130. The stock's 50-day moving average price is $5.11 and its two-hundred day moving average price is $4.91. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $12.40. The stock has a market capitalization of $390.94 million, a price-to-earnings ratio of 17.58 and a beta of 1.42.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.16. The business had revenue of $23.19 million for the quarter, compared to analysts' expectations of $7.23 million. Monte Rosa Therapeutics had a return on equity of 9.95% and a net margin of 13.58%.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets purchased a new position in Monte Rosa Therapeutics in the 4th quarter valued at about $43,000. Brighton Jones LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 2nd quarter worth $48,000. Lazard Asset Management LLC lifted its position in Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company's stock valued at $48,000 after acquiring an additional 3,262 shares during the last quarter. Focus Partners Wealth purchased a new stake in shares of Monte Rosa Therapeutics in the fourth quarter valued at about $77,000. Finally, Prudential Financial Inc. acquired a new stake in Monte Rosa Therapeutics during the 2nd quarter worth approximately $54,000. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.